# Ascendo Biotechnology

Source: https://onco.cc/companies/ascendo-biotechnology/  
OnCo record `ascendo-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ascendo Biotechnology makes an antibody that releases a brake on the body's first-line immune cells, aiming to help the immune system attack solid tumours that resist current immunotherapy.

## Summary

Ascendo Biotechnology Inc., headquartered in Taipei, was founded in 2019 as a spin-out from BRIM Biotechnology, according to the company, by Dr Yen-Ta Lu of MacKay Memorial Hospital. It targets the TLT-1/CD11b innate immune checkpoint axis. ASD141, a first-in-class anti-CD11b monoclonal antibody that blocks TLT-1 signalling, is in a first-in-human phase 1 trial in advanced solid tumours (NCT06235437); ASD001, a CD11b-activating antibody for autoimmune disease, is preclinical. In May 2026 it completed an oversubscribed Series A with investors including Taiwania Capital (TaiAx Life Science Fund), Yuanta Venture Capital and Industrial Technology Investment Corporation. Its first registered cancer trial, NCT06235437, was posted on ClinicalTrials.gov in February 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Ascendo Biotechnology Inc.; 先知生物科技
- HQ: Taipei
- Type: biotech
- Website: https://www.ascendobiotech.com/

## Notes

- Founding year, spin-out origin and Taipei address from the company's About and Contact pages, read on 29 October 2026. The Series A release does not state an amount. None of the named investors has an OnCo investor record.

## Sources

- Official website: https://www.ascendobiotech.com/
- Series A release, May 2026: https://www.ascendobiotech.com/2026/05/08/ascendo-biotechnology-completes-oversubscribed-series-a-financing-to-advance-innate-immune-checkpoint-pipeline/
- ClinicalTrials.gov: phase 1 trial of ASD141 (NCT06235437): https://clinicaltrials.gov/study/NCT06235437

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD11b](https://onco.cc/targets/cd11b/)

---
JSON: https://onco.cc/api/v1/entities/ascendo-biotechnology.json